Braf gene fusions and uses thereof
AssigneeFoundation Medicine, Inc.
InventorsHanna TUKACHINSKY, Alexa B. SCHROCK
Life of this patent
Estimating the term…
Abstract
Provided herein are nucleic acids encoding BRAF fusions or BRAF fragments, BRAF fusion polypeptides, and BRAF polypeptide fragments, methods related to detecting BRAF fusions or BRAF fragments, BRAF fusion polypeptides, and BRAF polypeptide fragments in cancer, as well as methods of treatment and uses related thereto. Detection of a BRAF fusion, BRAF fragment, BRAF fusion polypeptide, or BRAF polypeptide fragment can be used to identify individuals that may benefit from treatment with an anti-cancer therapy.
Claims22
A method of treating or delaying progression of cancer in an individual, comprising:
- (a) acquiring knowledge of a BRAF nucleic acid molecule, or a BRAF polypeptide encoded by the BRAF nucleic acid molecule, in a sample from the individual, wherein:
- (i) the BRAF nucleic acid molecule is a BRAF fusion nucleic acid molecule comprising a fusion between a BRAF gene, or a portion thereof, and a fusion partner gene as listed in Table 1A, or a portion thereof;
- (ii) the BRAF nucleic acid molecule is a BRAF fusion nucleic acid molecule comprising a fusion between a BRAF gene, or a portion thereof, and a fusion partner gene as listed in Table 1B, or a portion thereof, wherein the cancer is a prostate cancer;
- or
- (iii) the BRAF nucleic acid molecule is a BRAF gene fragment encoding a BRAF kinase domain, or a functional fragment thereof, wherein the BRAF gene fragment does not comprise one or more of BRAF exons 1-10 or has been decoupled from a BRAF regulatory domain;
- and
- (b) responsive to said knowledge, administering to the individual an effective amount of a treatment that comprises a BRAF-targeted therapy.
A method of treating or delaying progression of cancer in an individual, comprising administering to an individual having cancer an effective amount of a treatment that comprises a BRAF-targeted therapy, wherein the BRAF-targeted therapy is administered responsive to acquiring knowledge of a BRAF nucleic acid molecule, or a BRAF polypeptide encoded by the BRAF nucleic acid molecule, in a sample from the individual, wherein:
- (a) the BRAF nucleic acid molecule is a BRAF fusion nucleic acid molecule comprising a fusion between a BRAF gene, or a portion thereof, and a fusion partner gene as listed in Table 1A, or a portion thereof;
- (b) the BRAF nucleic acid molecule is a BRAF fusion nucleic acid molecule comprising a fusion between a BRAF gene, or a portion thereof, and a fusion partner gene as listed in Table 1B, or a portion thereof, wherein the cancer is a prostate cancer;
- or
- (c) the BRAF nucleic acid molecule is a BRAF gene fragment encoding a BRAF kinase domain, or a functional fragment thereof, wherein the BRAF gene fragment does not comprise one or more of BRAF exons 1-10 or has been decoupled from a BRAF regulatory domain.
A method of treating or delaying progression of cancer, comprising:
- (a) detecting a BRAF nucleic acid molecule, or a BRAF polypeptide encoded by the BRAF nucleic acid molecule, in a sample from an individual having a cancer, wherein:
- (i) the BRAF nucleic acid molecule is a BRAF fusion nucleic acid molecule comprising a fusion between a BRAF gene, or a portion thereof, and a fusion partner gene as listed in Table 1A, or a portion thereof;
- (ii) the BRAF nucleic acid molecule is a BRAF fusion nucleic acid molecule comprising a fusion between a BRAF gene, or a portion thereof, and a fusion partner gene as listed in Table 1B, or a portion thereof, wherein the cancer is a prostate cancer;
- or
- (iii) the BRAF nucleic acid molecule is a BRAF gene fragment encoding a BRAF kinase domain, or a functional fragment thereof, wherein the BRAF gene fragment does not comprise one or more of BRAF exons 1-10 or has been decoupled from a BRAF regulatory domain;
- and
- (b) administering to the individual an effective amount of a treatment that comprises a BRAF-targeted therapy.
(canceled)
(canceled)
Dependencies are inferred from the claim text.